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Background: Blockade of human epidermal growth factor receptor type 2 (HER2) has dramatically improved outcome for patients
with HER2-positive breast cancer. Trastuzumab, an anti-HER2 monoclonal antibody, has previously demonstrated improvement in
overall survival (OS) in patients with metastatic and early stage HER2-positive breast cancer. However, trastuzumab can cause
congestive heart failure (CHF) with an increased frequency for patients who have also received an anthracycline. The current trial
was designed to evaluate the impact of the duration of trastuzumab on CHF.
Methods: E2198 included 227 eligible women with histologically confirmed stage II or IIIA HER2-positive breast cancer.
The patients were randomised to receive 12 weeks of paclitaxel and trastuzumab followed by four cycles of doxorubicin and
cyclophosphamide (abbreviated Arm) or the aforementioned treatment with additional 1 year of trastuzumab (conventional Arm).
The primary end point was to evaluate the safety of this variable duration of trastuzumab therapy, particularly cardiac toxicity
defined as CHF or left ventricular ejection fraction decrease 410%. Secondary end points included disease-free survival (DFS)
and OS.
Results: Compared with 12-week treatment with trastuzumab, 1 year of trastuzumab-based therapy did not increase the frequency
or severity of cardiac toxicity: three patients on the abbreviated Arm and four on the conventional Arm experienced CHF. The 5-
year DFS was 76% and 73% for the abbreviated and conventional Arms, respectively, with a hazard ratio (HR) of 1.3 (95% CI: 0.8–
2.1; P¼ 0.3). There was also no statistically significance difference in OS (HR, 1.4; P¼ 0.3).
Conclusions: Compared with 12 weeks of treatment, 1 year of treatment with trastuzumab did not significantly increase the risk of
cardiac toxicity. Although not powered for efficacy comparisons, the longer duration of trastuzumab therapy did not demonstrate
a signal for marked superiority.
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Blockade of human epidermal growth factor receptor type 2
(HER2) has dramatically improved outcome in both the metastatic
and adjuvant settings for tumours with HER2 overexpression or
gene amplification (Slamon et al, 2001; Piccart-Gebhart et al, 2005;
Romond et al, 2005; Slamon et al, 2011). Multiple anti-HER2
agents have demonstrated improvement in progression-free
survival (PFS) and/or overall survival (OS) for patients with
metastatic disease (Geyer et al, 2006; Verma et al, 2012; Swain et al,
2015). The use of trastuzumab in the adjuvant setting has also
demonstrated improvement in OS when added to a backbone of
chemotherapy compared with chemotherapy alone (Slamon et al,
2001). Many other agents used in the metastatic setting are
actively being tested in the adjuvant and neoadjuvant settings.
Although the therapeutic indices for these agents are excellent,
trastuzumab is not void of toxicity. Specifically, congestive heart
failure (CHF) is the most serious toxicity (Telli et al, 2007) and its
frequency is increased when combined with an anthracycline
(Romond et al, 2012).
Currently, the optimal duration of adjuvant trastuzumab
therapy for patients with HER2-positive disease is 1 year (Pivot
et al, 2013). This duration was based on the results of two major
trials. The HERA trial demonstrated that 2 years of trastuzumab
therapy after standard chemotherapy did not improve disease-free
survival (DFS) nor OS compared with 1 year of trastuzumab
therapy (Piccart-Gebhart et al, 2005). The PHARE trial compared
the outcome of 1 year of trastuzumab therapy with 6 months
trastuzumab therapy. This was a non-inferiority trial and
demonstrated that outcome of trastuzumab administration for 6
months was not non-inferior to the same for 12 months (Pivot
et al, 2013). Even shorter durations of trastuzumab, however, have
been compared with no therapy and have demonstrated activity.
Specifically, the FINHER trial showed that 3 months of adjuvant
trastuzumab was superior to none (Joensuu et al, 2009). E2198 was
primarily designed to evaluate the impact of duration of
trastuzumab on CHF. Here we also report the results for a
comparison of the conventional 1-year duration trastuzumab
therapy with a shorter exposure in the adjuvant setting.
PATIENTS AND METHODS
Study design and treatment. E2198 was a randomised phase II
study (Figure 1). All patients were pre-registered to the
pre-randomisation Arm and tumour blocks were sent to the
ECOG-ACRIN Pathology Coordinating Office for central review of
HER2 status. Patients with a score of 2–3þ determined by
immunohistochemistry (IHC) were classified as eligible for
randomisation to an abbreviated trastuzumab Arm or a conven-
tional trastuzumab Arm. Treatments were assigned using per-
muted blocks within strata with dynamic balancing within main
institutions and their affiliate networks. Patients were stratified
based on whether radiation therapy was planned vs not planned.
All patients received paclitaxel 175mgm 2 on day 1 every 3 weeks
for four cycles and trastuzumab with a 4mg kg 1 loading dose in
week 1 followed by 2mg kg 1 weekly through week 10 (TH).
Three weeks after the last doses of TH, patients received
doxorubicin 60mgm 2 and cyclophosphamide 600mgm 2 on
day 1 every 3 weeks for four cycles (AC). Within 3 weeks after
the completion of AC and completion of radiation therapy
(if administered), patients randomised to the conventional Arm
received additional trastuzumab with a 4mg kg 1 loading dose in
week 1 followed by 2mg kg 1 weekly for 1 year (Figure 1).
Radiation therapy, if clinically indicated, was administered
according to institutional guidelines after the completion of AC.
Patients with tumours classified as oestrogen receptor (ER) and/or
progesterone receptor (PgR) positive must have received tamoxifen
at the completion of AC for 5 years. For patients randomised to the
conventional Arm, tamoxifen could have been administered
concomitantly with the maintenance trastuzumab.
Patients. Female patients X18 years old with histologically
confirmed stage II or IIIA HER2-positive breast cancer were
eligible if they had not received previous chemotherapy or
hormonal therapy. Patients who had received previous tamoxifen
for chemoprevention were required to have discontinued tamox-
ifen for at least 1 year before enrolment. Patients who had their last
definitive surgical procedure within the previous 12 weeks before
receiving radiation therapy were considered eligible. Additional
inclusion criterial included adequate cardiac function with a left
ventricular ejection fraction (LVEF) X50%, and adequate renal,
hepatic and haematological function.
Patients were excluded if they had a history of congestive
cardiomyopathy, CHF, uncontrolled hypertension, myocardial
infraction or uncontrolled arrhythmia within the prior 6 months.
Patients were also excluded if they had another cancer within the
previous 5 years except basal or squamous cell carcinoma of the
skin or in situ cervical cancer.
Methods. Assessments of the patient’s overall health, history,
physical exam and performance status were performed at baseline,
day 1 of each cycle, and then post AC every 3 months for the first
year, every 6 months for the second year and then annually.
Haematological evaluations were obtained with the same frequency
with additional tests between TH and at the start of AC and during
each cycle. A chest X-ray and EKG were required at baseline. LVEF
was to be performed via MUGA or echocardiogram (as long as the
method was consistent) at baseline, post TH, post AC, 1 year post
AC (abbreviated arm only) and at the following three time points
for the conventional Arm: 6 months after beginning maintenance
trastuzumab; within 1 month of completing; and 1 year post
maintenance trastuzumab. Annual mammograms were required
with the long-term follow-up form submitted each time that a
patient was seen.
Since the standard definition of HER2 positivity was either 2þ
or 3þ with the HercepTest (DAKO, Carpinteria, CA, USA) when
this trial was conducted, we repeated the HER2 scoring centrally
(for available cases) using IHC and reflex FISH in November 2013
according to the College of American Pathologist (CAP) guidelines
(Wolff et al, 2013). Those patients with an IHC of 0 or, 1þ were
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Figure 1. Trial schema.
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considered HER2-negative, whereas those with 3þ were con-
sidered positive. Those patients who were 2þ were tested by FISH.
Patients were considered HER2-negative with a HER2/CEP17 ratio
o1.8; positive with a ratio X2.2; and equivocal with a ratio X1.8
and o2.2.
Statistical considerations. The primary objective was to evaluate
the safety of these treatment regimens, particularly with respect to
CHF and LVEF. Toxicities were graded according to the Common
Toxicity Criteria (CTC) version 2.0. CHF (defined as grade 3-4
LVEF dysfunction), Grade 3-4myocarditis, and decreases in LVEF
of 410% were of interest. The study was originally designed to
enrol a total of 100 eligible patients. The accrual goal was later
increased to allow entry of 200 eligible patients in order to better
assess the cardiac toxicity. CHF rate was summarised as a
proportion with corresponding exact 95% confidence interval
(CI). Fisher’s exact test was used to compare Arms with respect to
proportion with 410% decrease in LVEF post TH and post AC.
The proportion of patients with 410% decrease in LVEF 1 year
post AC treatment and 1 year post maintenance trastuzumab was
also evaluated. Although the trial was not powered for time-to-
event comparisons, secondary end points included DFS and OS.
DFS was defined as time from randomisation to disease recurrence,
development of invasive second primary or death. Patients without
documented DFS event were censored at date of last disease
evaluation. Survival was defined as the time from randomisation to
death from any cause, otherwise censored at date last known alive.
Distributions of DFS and OS were estimated using the Kaplan–
Meier method. Toxicity summaries included all patients who
received protocol treatment. Summaries of baseline demographics,
disease characteristics, and analysis of outcome data included
eligible patients. Two-sided P-values o0.05 were considered
statistically significant.
RESULTS
Patients and treatment. Pre-registration of E2198 began in
August 1999, but suspended on 23 February 2000 while an
amendment to increase accrual was under review. The pre-
registration was re-activated in May 2000 and closed in October
2000. A total of 303 patients were originally pre-registered to pre-
randomisation Arm and 234 were randomised to the abbreviated
or conventional trastuzumab Arm. However, only 227 patients met
the eligibility criteria, of whom 115 were assigned to abbreviated
and 112 conventional trastuzumab Arm (Figure 1). The two groups
of patients were well balanced at baseline with respect to
prognostic characteristics (Table 1). The median age was 49 years
(range 22–78). Approximately 54% of the patients had 1–3 positive
lymph nodes, 29% had 4–9 positive nodes and 17% had 10 or more
positive nodes. Sixty two percent of the patients had ER- and/or
PgR-positive tumours. Patients received a median of eight cycles of
the treatment for both Arms (range, 2–8); 93% and 87% of patients
on abbreviated and conventional Arms completed protocol
treatment through AC, respectively. Out of the 112, 90 patients
on conventional Arm (80%), including nine patients who did not
complete eight cycles of TH-AC, began the maintenance
treatment of trastuzumab. Out of these 90, 67 patients (74%)
completed the entire duration of maintenance trastuzumab.
Therefore 60% of the patients assigned to conventional Arm
completed treatment per protocol.
In November 2013, HER2 status was reassessed based on more
contemporary definitions. Samples from 176 patients were
available for repeat testing (Supplementary Figure 1). Tumours
from 31 out of the 176 patients (17.6%) that were previously
classified as HER2-positive were found to be 0 or 1þ by IHC, and
thus reclassified as HER2-negative; 105 patients (59.7%) were 3þ
and thus confirmed as HER2-positive; 40 patients (22.7%) were
HER2 2þ and subsequent tested by FISH: 9 out of 40 patients did
not have sufficient additional material for FISH and were removed
from further analyses; 15 had HER2 amplification and 16 did not.
In total, 120 patients were confirmed with HER2-positive tumours
by more contemporary definitions of positivity. Except for a minor
difference in median age (median 47 for those confirmed HER2þ
and 51 for those not), there were no differences with respect to
baseline demographics and disease characteristics between those
patients confirmed HER2þ vs those not.
Safety. Seven out of the 234 patients (3%) had CHF (95% CI,
1.2–6%) including one patient with grade 3 myocarditis; three of
the patients were on the abbreviated Arm and four on the
conventional Arm. There were no differences between Arms in the
proportion with LVEF decrease 410% post TH treatment
(P¼ 0.6) or post AC therapy (P¼ 0.6) (Table 2). Patients had no
unexpected frequency or severity of toxicity related to the similar
treatment combination (Supplementary Table 1). No lethal
toxicities were observed.
Efficacy. Data reported here are as of November 2013 at a median
follow-up of 77 months. Efficacy was evaluated separately in the
227 patients enrolled and randomised in the trial, and in the 120
patients re-tested centrally and HER2-positive. Figure 2 shows the
Kaplan–Meier curves for DFS and OS of the aforementioned two
groups of patients randomised into the two Arms. For the 227
patients, there was no statistically significant difference in DFS (HR
for conventional (29 recurrences) vs abbreviated (25 recurrences),
1.3; 95% CI, 0.8–2.1; P¼ 0.3; 5-year DFS, 73 and 76%, respectively)
or OS (HR, 1.4; P¼ 0.3; 5-year OS, 83 and 89%, respectively)
(Table 3a). For the 120 patients, there was no significant difference
in either DFS (HR, 0.9; P¼ 0.7; 5-year, DFS 78% and 74%,







Race – no. (%)
White 106 (92) 97 (87)
Hispanic 2 (2) 3 (3)
Black 4 (3.5) 9 (8)
Other 3 (2.5) 3 (2)
Age (years) – no. (%)
o40 21 (18) 21 (19)
X40 94 (82) 91 (81)
Age – median (range) 49 (26–78) 48 (22–76)
Nodal status – no. (%)
1–3 positive nodes 58 (51) 64 (57)
4–9 positive nodes 35 (30) 32 (29)
X10 positive nodes 22 (19) 16 (14)
Number of positive nodes –
median (range)
3 (1–29) 3 (1–24)
ER/PgR status – no. (%)
ER /PgR 45 (39) 41 (37)
ER /PgRþ 6 (5) 5 (14)
ERþ /PgR 9 (9) 16 (4)
ERþ /PgRþ 54 (47) 50 (45)
Missing 1 (1) 0 (0)
ECOG performance status – no. (%)
0 100 (87) 99 (88)
1 14 (12) 12 (11)
2 1 (1) 1 (1)
Most extensive surgery – no. (%)
Less than mastectomy 32 (28) 41 (36)
Modified radical mastectomy 70 (61) 59 (53)
Total (simple) mastectomy 13 (11) 12 (11)
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respectively) or OS (HR, 1.2; P¼ 0.7; 5-year OS, 89% and 94%,
respectively) (Table 3b).
DISCUSSION
Targeting HER2 has drastically improved the outcome for patients
with HER2-positive breast cancer. In the metastatic setting, the
addition of trastuzumab to chemotherapy significantly improved
both PFS and OS. The addiction to this pathway has been
evidenced by continued benefit to anti-HER2 blockade even after
progression on trastuzumab (Geyer et al, 2006; Schaller et al, 2007).
More recently, dual blockade with trastuzumab and either lapatinib
or pertuzumab has also demonstrated further improved PFS and
OS in the metastatic setting (Swain et al, 2015). Trastuzumab has
improved DFS and OS in the adjuvant setting compared with
chemotherapy alone (Slamon et al, 2011). Although dual therapy
with trastuzumab plus pertuzumab and trastuzumab plus lapatinib





Baseline and post TH LVEF available – no. 112 111
Median post TH LVEF – no. 61 61
Post TH LVEF decline 410% – no. (%) 12 (11) 9 (8)
Post TH LVEF decline 410% and LVEF oLLN – no. (%) 3 (3) 1 (1)
Baseline and post AC LVEF available – no. 95 104
Median post AC LVEF – no. 59 60
Post AC LVEF decline 410% – no. (%) 15 (16) 13 (13)
Post AC LVEF decline 410% and LVEF oLLN – no. (%) 3 (3) 5 (5)
Baseline and post 1 year of treatmenta LVEF available – no. 78 40
Median post 1 year of treatment LVEF – no. 62 63
Post 1 year of treatment LVEF decline 410% – no. (%) 13 (17) 9 (23)
Post one year of treatment LVEF decline 410% and LVEF oLLN – no. (%) 1 (1) 2 (5)
Abbreviation: LVEF¼ left ventricular ejection fraction.
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Figure 2. (Top) Comparison of DFS (left) and OS (right) for the 227 patients enrolled and randomised. (Bottom) Comparison of DFS (left) and OS
(right) for the 120 patients centrally re-tested and HER2-positive.
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demonstrated an improvement in pathological complete response
over trastuzumab alone, the addition of lapatinib to trastuzumab
did not improve either DFS or OS in the large adjuvant ALTTO
trial (Piccart-Gebhart et al, 2014). We now await the results of the
APHINITY trial, testing the combination of pertuzumab with
trastuzumab, to determine whether we have truly reached a plateau
in terms of benefit from single agent HER2 blockade. From a
duration standpoint, recently the ExteNET trial (Chan et al, 2015)
reported improved invasive DFS in early stage HER2-positive
breast cancer patients who received neratinib after completion of 1
year of trastuzumab. It is not clear if this improvement was due to
a longer duration of therapy or the addition of second effective
anti-HER2 therapy. The HERA trial included a comparator arm
that focused entirely on duration and demonstrated that 2 years of
trastuzumab administration does not confer benefit over 1 year,
suggesting we may have reached a duration plateau for single agent
therapy (Piccart-Gebhart et al, 2005). Although we may have
reached a ceiling in terms of incremental benefit from the amount
and the duration of HER2 blockade, many questions remain as to
whether we can minimise the amount of chemotherapy and
trastuzumab in specific populations and whether less than 12
months of therapy may be beneficial. Recent data have demon-
strated that women with small tumours (T1c) may indeed benefit
from HER2 blockade (O’Sullivan et al, 2014); although the
outcomes for T1a/T1b tumours appear to have exceptionally good
outcome in the absence of additional therapy. In addition, Tolaney
et al. (2015) demonstrated that the use of single agent paclitaxel
and trastuzumab alone might provide outstanding efficacy for
small, node-negative tumours. Thus, there are many evidence-
based options for patients diagnosed with early stage HER2-
positive breast cancer; ranging from traditional full doses of
chemotherapy with dual antibody blockade to single agent
paclitaxel and trastuzumab in the adjuvant setting. Shorter
durations of trastuzumab have also recently been reported. The
PHARE trial (Pivot et al, 2013), which was a non-inferiority trial,
could not exclude the inferiority of 6 months of trastuzumab
compared with 1 year. Despite this, there is some evidence of
benefit to the use of trastuzumab for shorter durations compared
with none (Joensuu et al, 2009). Thus, it is not clear where on the
risk spectrum that the incremental gain in outcome from longer
therapy can be optimally captured.
Opened to accrual in 1999, E2198 was designed to capture the
toxicity for various durations of trastuzumab therapy; most
importantly cardiac toxicity. The previously reported rates of
CHF from the large adjuvant trastuzumab trials are consistently
low (o4% incidence) (Ewer et al, 2005; Suter et al, 2007; Perez
et al, 2008; Procter et al, 2010; Russell et al, 2010; Pivot et al, 2013;
de Azambuja et al, 2014). Exposure to anthracyclines, low baseline
ejection fraction, older age, hypertension and high BMI appear to
predict a higher likelihood (Perez et al, 2008; Russell et al, 2010;
Bowles et al, 2012). The majority of patients who experience severe
cardiac toxicity, however, do appear to have either partial or
complete recovery of function with cessation of therapy (Ewer et al,
2005; Procter et al, 2010; Russell et al, 2010; de Azambuja et al,
2014). Two years of trastuzumab did not increase the risk of severe
cardiac damage compared to one year in the HERA trial (de
Azambuja et al, 2014). There was a significantly higher rate of CHF
for those receiving 1 year of therapy compared with 6 months in
the PHARE study, but the rates were very low in both arms with
recovery in the vast majority of patients (Pivot et al, 2013). As
expected from these prior reports, there were no unexpected
toxicities for the combination of chemotherapy with trastuzumab.
Specifically, the rates of CHF and drops in LVEF 410% were
modest and not substantially different based on duration of
therapy. Unfortunately this trial used the older CTCv. 2.0 criteria
for scoring and there was neither central review nor long-term
follow-up, which is a limitation of this study.
Although this trial was not powered for efficacy outcome
comparisons, there appeared to be no substantial signal to
demonstrate marked benefit for longer duration. Thus, while these
data should not challenge the current standard of care for one year
of anti-HER2 therapy, it does add to the existing body of data to
support some benefit for even short durations of trastuzumab. For
patients with low-risk disease, where the value of therapy was
uncertain at the outset and where cardiac (or other toxicity) issues
become apparent, it may provide support to truncate therapy
early with some benefit, rather than extending therapy to
complete an entire year of therapy. These efficacy results must
be interpreted with caution because of the different definition of
HER2 positivity at the time of the trial initiation. To address this
concern, we centrally repeated HER2 testing using more
contemporary definitions of HER2 positivity. It must be noted
that several patients were removed simply because of lack of
sufficient tumour material for testing or were found to be HER2
equivocal. In addition, even for those patients clearly HER2-
negative on re-testing, these tumours may have had molecular
heterogeneity and thus have gained benefit despite the negative
test. Further, there are some data to support benefit from those
with even low levels of HER2 protein expression (Paik et al,
2008). Regardless, in both the parent group and retested subset,
there was no substantial improvement in outcomes for the longer
duration of therapy.
In summary, this trial supports the safety of combining
chemotherapy with trastuzumab. Further, although underpowered
and exploratory, it identified no substantial signal for marked
inferiority for a shorter duration of trastuzumab. Although 1 year
of anti-HER2 blockade should remain the standard of care, this
adds additional data to support efficacy for shorter durations and
this may be beneficial for decision making in patients having
difficulty in tolerating the therapy. In addition, from a global
perspective, 1 year of trastuzumab administration for every patient
with HER2-positive breast cancer may simply not be feasible from
a financial standpoint (Benjamin et al, 2013). Thus, additional
trials addressing shorter durations remain critical.










DFS 1.31 (0.79–2.12) 0.31 76% 73%
OS 1.37 (0.74–2.54) 0.32 89% 83%
Abbreviations: CI¼ confidence interval; DFS¼disease-free survival; OS¼overall survival.
aHazard ratio for conventional trastuzumab vs abbreviated trastuzumab.
bBased on log-rank test.











DFS 0.85 (0.41–1.77) 0.66 74% 78%
OS 1.21 (0.46–3.13) 0.70 94% 89%
Abbreviations: CI¼ confidence interval; DFS¼disease-free survival; HER2¼ human epider-
mal growth factor receptor type 2; OS¼overall survival.
aHazard ratio for conventional trastuzumab vs abbreviated trastuzumab.
bBased on log-rank test.
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